Aminolevulinic Acid 20% Topical Solution Activated by Blue Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in situ
Main Article Content
Keywords
ALA-PDT, blue light, Red light, Aminolevulinic Acid, Cutaneous Squamous Cell Carcinoma, Squamous cell carcinoma in situ (SCCIS)
Abstract
Cutaneous squamous cell carcinoma in situ (isSCC) commonly affects sun-exposed facial skin, whereas non-surgical options may be desirable in certain anatomic locations. In this study, 30 patients with biopsy-confirmed facial isSCC received two aminolevulinic acid photodynamic therapy (ALA-PDT) treatments, spaced 28 days apart, followed by a histopathological exam,. Of the 30 patients, 100% achieved clinical and histological clearance. Local reactions were mild and transient, and adverse events were rare. ALA-PDT was safe, well tolerated, and yielded excellent cosmetic outcomes, supporting its role as a non-invasive treatment for facial isSCC.
References
2. Nestor MS, Han H, Ceci FM, Lawson A, Gade A. Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ. J Cosmet Dermatol. 2023;22(9):2471-2475. doi:10.1111/jocd.15886
3.Nestor MS, Berman B, Patel J, Lawson A. Safety and Efficacy of Aminolevulinic Acid 10% Topical Gel versus Aminolevulinic Acid 20% Topical Solution Followed by Blue-light Photodynamic Therapy for the Treatment of Actinic Keratosis on the Face and Scalp: A Randomized, Double-blind Study. J Clin Aesthet Dermatol. 2019;12(3):32-38.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.